What evidence does the NHS need
before it adopts a health innovation?

The NHS rarely adopts a health innovation on the strength of a good idea. It adopts on evidence. And the evidence it looks for falls into four clear categories: evidence that the innovation works, that it’s safe, that it offers value for money, and that it fits the way care is actually delivered. If you can speak to all four, you’re already ahead of many innovators.

The NHS sets a high bar for evidence.

The NHS is under real financial pressure, and every new tool competes for limited time, money and attention. Day-to-day health spending is projected to rise by around 2.2% a year to 2028/29 – below the long-run average – so buyers are cautious for good reason. A technology that fails after adoption costs money, disrupts clinical teams and erodes trust.

The gap between a promising pilot and routine use is rarely about the quality of the technology. It comes down to whether the evidence gives commissioners the confidence to say yes.

What kinds of evidence does the NHS look for?

Clinical effectiveness. Does an innovation improve outcomes, and how do we know for sure? The proof may be a clinical trial, a peer-reviewed study or robust real-world data. The bolder the clinical claim, the stronger the evidence needs to be.

Safety and regulatory compliance. Does the innovation meet the relevant standards? For a medical device, that means the correct UKCA marking and MHRA compliance. For digital tools, it means clinical safety standards such as DCB0129, data protection under UK GDPR, and cyber security assurance.

Economic value. Does the innovation save money, free up staff time or prevent costlier care later? A clear health-economic case – ideally a budget impact model – helps commissioners justify the spend.

Real-world fit. Does the innovation work inside an NHS pathway, with NHS systems and NHS staff? Evidence of usability, workflow fit and successful implementation often carries as much weight as the clinical data.

Which frameworks set the standard?

There’s no single framework — there are many, and the ones that apply depend on what you’re building and how it’ll be used. That said, a few come up again and again, and it pays to know them well.

Start with the regulator. The Medicines and Healthcare products Regulatory Agency (MHRA) governs whether an innovation can be legally and safely used in the UK. If your product qualifies as a medical device — and many digital tools do — MHRA requirements aren’t optional. Understanding them early is critical.

The NICE Evidence Standards Framework (ESF) sets out what good evidence looks like for digital health technologies. It scales the requirement to the risk: a simple wellbeing app is held to a lighter standard than a tool that informs a clinical decision. NICE health technology evaluation applies to higher-risk technologies and medicines. A positive NICE recommendation carries significant weight right across the system.

The Digital Technology Assessment Criteria (DTAC) is the NHS baseline for software-based tools. It covers clinical safety, data protection, technical security, interoperability, and usability. NHS buyers use it as a due-diligence check, often before a pilot can even begin. A refreshed version became the required form in April 2026, so make sure you’re working from the current one.

Which of these apply — and in what combination — depends on your innovation, your claims, and your route into the system. Mapping that early saves real delay and difficulty later.

How much evidence is enough?

Enough to match the risk. The NHS doesn’t expect a low-risk tool to carry the same evidence as one that guides a diagnosis. Over-engineering your evidence wastes time and budget; falling short stalls adoption. The skill lies in judging the right level – and building in evidence from the beginning as opposed to scrambling for it once a buyer asks.

This is where many innovators come unstuck. They can prove the technology works in a lab or a single site, then discover too late that they’re lacking a clear economic case, implementation evidence, or an answer to the question every commissioner asks: what changes for our patients, our staff and our budget?

How Future Care Capital helps

Future Care Capital is an independent partner working at the intersection of health innovation, evaluation, and impact investment. As an independent charity rather than a technology vendor, our guidance is impartial.

Our work helps innovators understand exactly what the NHS will ask for, build a credible evidence plan, and design evaluation that stands up to scrutiny.

We also translate that evidence into the language commissioners use, so a strong innovation isn’t held back by a weak case. Our aim is simple: to help good health innovations move from promising pilot to system-wide adoption, and to evidence the difference they make along the way.

If you’re building a health innovation and want to get the evidence right from the start, we’d be glad to talk. Contact our evaluation lead Prof. Andy Jones at andy@futurecarecapital.org.uk.